SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Concord Biotech - Quaterly Results

06 Sep 2023 Evaluate
A fair growth of 7.64% in the revenue at Rs. 1948.28 millions was reported in the June 2023 quarter as compared to Rs. 1810.01 millions during year-ago period.The Company has registered profit of Rs. 484.71  millions for the quarter ended June 2023, a growth of 12.46%  over Rs. 431.01 millions millions achieved in the corresponding quarter of last year.Operating Profit saw a handsome growth to 788.07 millions from 724.61 millions in the quarter ended June 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202306 202206 % Var
Sales 1948.28 1810.01 7.64 1948.28 1810.01 7.64 1948.28 1810.01 7.64
Other Income 66.54 78.31 -15.03 66.54 78.31 -15.03 66.54 78.31 -15.03
PBIDT 788.07 724.61 8.76 788.07 724.61 8.76 788.07 724.61 8.76
Interest 7.53 10.38 -27.46 7.53 10.38 -27.46 7.53 10.38 -27.46
PBDT 780.54 714.23 9.28 780.54 714.23 9.28 780.54 714.23 9.28
Depreciation 130.41 135.67 -3.88 130.41 135.67 -3.88 130.41 135.67 -3.88
PBT 650.13 578.56 12.37 650.13 578.56 12.37 650.13 578.56 12.37
TAX 165.42 147.55 12.11 165.42 147.55 12.11 165.42 147.55 12.11
Deferred Tax 2.42 4.25 -43.06 2.42 4.25 -43.06 2.42 4.25 -43.06
PAT 484.71 431.01 12.46 484.71 431.01 12.46 484.71 431.01 12.46
Equity 104.62 104.62 0.00 104.62 104.62 0.00 104.62 104.62 0.00
PBIDTM(%) 40.45 40.03 1.04 40.45 40.03 1.04 40.45 40.03 1.04

Concord Biotech Share Price

1059.30 -8.10 (-0.76%)
21-Apr-2026 12:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.00
Dr. Reddys Lab 1220.00
Cipla 1231.00
Zydus Lifesciences 928.25
Lupin 2322.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×